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Abstract: This letter to the editor highlights the important aspects of cancer stem cells and provides a deeper insight into the origin
and characterization of these cells as well as the mechanisms contributing to drug resistance and relapse. The two currently available
models (CSC and the clonal evolution model) need not be mutually exclusive to explain the origin of CSCs. The identification of CSCs
(based on surface markers, drug efflux, enzyme activity, and signal transduction molecules and proteins involved in EMT processes)
can help in discriminating these cells from other cell types. Moreover, CSCs prefer a hypoxic environment. This microenvironmental
cue can trigger certain metabolic alterations that can orchestrate a rewiring of the epigenome. Consequently, changes in transcription
factors and signaling molecules can contribute to the plasticity/inter-convertibility of the CSCs and non-CSC cellular states. Hence,
an improved understanding of the mechanisms involved also provides opportunities for pharmacological manipulations. This letter
also underscores the presence of precancerous stem cells as well as very small embryonic-like stem cells (VSELs) (both considered to
be precursors of CSCs). These reports warrant a thorough reanalysis of the source of CSCs (lineage tracing studies), subsequent to the
development of better targeted intervention approaches.
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1. Introduction
The alarmingly increasing incidence of cancer as a
major public health burden has necessitated the need to
reiterate the importance of identifying and selectively
targeting cancer cells so that the efficacy of the therapeutic
intervention can be improved with minimal side effects.
The research article entitled “Cancer stem cells:
emerging actors in both basic and clinical cancer research”
highlights the role of cancer stem cells (CSCs) (a pivotal
cell type occupying a specialized niche in the tumor
microenvironment and playing a major role not only
in terms of tumor initiation but also in recurrence and
metastasis) as attractive targets for drug developers and
provides fairly concrete evidence for the same. This letter
will serve to highlight the important aspects cited therein,
with a deeper insight in terms of their origin, detection,
and characterization. Further, this letter aims to provide
a glimpse into some of the current pharmacological
approaches of selective elimination, thereby underscoring
the reviewed druggable targets.
* Correspondence: p.k.suresh@vit.ac.in

2. Origin and models
The relative contribution (singly or in combination) of the
different mechanisms to the origin of CSCs (mutations,
dedifferentiation of differentiated cells or committed
progenitor cells, or due to gain-of-function mutations)
would help in refining or identifying new targets for
drug development. The CSC concept is discussed in
the context of tumor heterogeneity as well as the clonal
evolution models, even though both processes may be
occurring (albeit to different extents in different tumors).
It has been shown that there is functional heterogeneity
(the clonal evolution model), especially tolerance to
chemotherapeutic agents, despite genetic stability, as
postulated by the cancer stem cell model (Kreso et al.,
2013). On the other hand, in other cancers the subclones
are complex and genetically variegated. The acquisition
of copy number changes is independent and reiterative
in the subclones of individuals, with no preference with
respect to the order (“stochastically varying intrinsic
factors”) (Anderson et al., 2011). Apart from etiology, the
determination of heterogeneity in cancer stem cell subsets
would help in better tailoring the dosage regimen. There
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is evidence that precancerous stem cells (associated with
precancerous lesions) may be the precursors of cancer
stem cells (found in primary cancer foci) and coevolve
with disease progression in terms of pathological features.
These primary cells acquire migratory capabilities,
and hence can metastasize to sites distant from their
origin. These phenotypically heterogeneous cells exhibit
differential sensitivity to radio and chemotherapies, and
hence present challenges to the oncologist/drug developer
in terms of identifying, localizing, and selectively targeting
these cells (horizontal versus vertical hierarchy) (Liu
et al., 2011). These cells express embryonic stem cellrelated genes (Pouf1/Otc4, TDGF1, Zfp42/REX1 and
Mili). They develop into benign and malignant tumors
in immunocompetent and SCID mice, respectively.
This concept presents exciting possibilities (for the drug
developer) since the malignant versus the benign status of
the tumor depends on the potentially modulatable tumor
microenvironment, with the possible regulation of piwil2
(Mili) playing a role in this process (Chen et al., 2007).
3. Identification and isolation of CSCs
3.1. Cell-surface markers
It is well recognized that flow cytometry-based surface
marker analysis is the method of choice for the
identification of CSCs. However, (as recognized by the
authors) due to the overlap in marker expression between
CSCs and other cell types (plasticity and heterogeneity),
it is now known that other proteins would also have to
be measured for their unique identification, apart from
correlating their expression with proliferation assays
(Cheli et al., 2014). On the other hand, label-free (based on
microfluidics and/or nanotechnology and/or biophysics)
methods for the identification of cells and CSCs are
increasingly being reported in the literature to circumvent
the need to define and accurately identify a biomarker
(Gossett et al., 2010; Uckermann et al., 2014; Lee and
Chang, 2014) using immunolabeling methods that have
been reported to be unreliable. Apart from their utility in
terms of their identification, they can be actively targeted
using monoclonal antibodies. For example, monoclonal
antibodies against CD44+, expressed in a subset of cells in
a 3D culture from the MCF-7 breast cancer cell line, were
conjugated to gold nanorods to selectively ablate these
cells exploiting the “receptor-seeking” capabilities of the
MAB and the photothermal properties of the nanorods at
the target site (Lee et al., 2012).
The aforesaid label-free methods can be extended to
identify circulating tumor cells (CTCs) (subpopulations
of which have been shown to have stem cell-like
features (Weller et al., 2014)) and can possibly replace
immunolabeling studies, following their validation
using conventional immunocytochemical and in situ
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hybridization-based approaches. In this regard, it is
increasingly being recognized the 4D models may be
better models for drug testing (Vishnoi et al., 2014)
and their transcriptional, translational, and in vitro
characteristics are different from those obtained from
their 2D counterparts (Mishra et al., 2015).
3.2. Dye exclusion assays
Dye efflux assays (due to the increased expression of drug
efflux transporters, especially in the side population fraction) and flow cytometry-based identification of surface
markers are among the currently available methods to
identify CSCs. These assays are complemented by the colony and sphere-forming assays. However, the SP fraction
is not a unique property of cancer stem cells. Hence, the
authors have recognized the need for a marker that is universal for stem cells of all types as well as an “identification
tag” unique for CSCs. Further, a blockade of drug efflux
transporters [ABCG2 (BCRP), known to be expressed in
side population (SP) cells by nanomolar concentration of
Tariquidar analogues, causes reversal of drug resistance
(Kühnle et al., 2009).
3.3. ALDH activity
The need to identify a universal maker for all types of
stem cells, including CSCs, has prompted aldehyde
dehydrogenase (ALDH) isozyme profiling (e.g., ALDH1)
and correlatable functional studies such as proliferation,
adhesion, and apoptosis-based assays (Ma and Allan,
2011). In another neurosphere study, ALDH1A2 was
correlated with a less differentiated phenotype that was
resistant to 13-cis-RA, and was involved in CSC regulation;
it also correlated with poor prognosis (Hartomo et al.,
2014). Such approaches would complement the ongoing
efforts to use a combination of markers to more accurately
identify the source of CSCs and discriminate them from
other types of stem cells.
3.4. Anchorage-independent cell culture
As stated by the authors, spheroid cultures are considered
to be better models in comparison with 2D cultures, both
for modeling cancer as well as for drug testing. Specifically,
mammospheres (either from MCF-7 or MDA-MB-231)
with an increase in Nrf2 demonstrated anchorageindependent growth, lower intracellular ROS levels, and
a relatively increased resistance to chemotherapeutic
agents. Brusatol has been shown to inhibit Nrf2, increase
sensitivity to drugs, and suppress anchorage-independent
growth (Wu et al., 2014). However, as stated by the authors,
the obtained results should be validated in vivo since the
artificial environment imposes selection pressures that do
not accurately mimic the internal milieu of the tumor and
its microenvironment.
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3.5. Signaling pathways and currently available drug
targeting strategies
The authors have summarized the importance of targeting
Notch, Wnt/β-catenin, and Sonic Hedgehog in cancer
stem cells. For example, cyclopamine, a SHH antagonist,
has been shown to selectively deplete glioblastoma cancer
stem cells in contrast to radiation treatment, which targets
the more differentiated neoplastic cells, but enriches these
stem cells (Barr et al., 2007)!!!
3.6. CSC niche and hypoxia
The authors have stated that the cancer stem cells prefer
to reside in a hypoxic environment. This aspect is significant since metabolic alterations (one of the emerging
hallmarks of cancer (Hanahan and Weinberg, 2011)) can
be important events contributing to the rewiring of the
epigenome (including a more permissive chromatin conformation), thereby facilitating the acquisition of the CSC
phenotype. This metabostemness property is amenable to
pharmacological manipulation (Menendez and Alarcón,
2014). More specifically, the Warburg effect may be acting
as a metabolic facilitator for the transcription factors and
signaling molecules that orchestrate the signals (intrinsic
and/or microenvironmental – for example, hypoxia as
stated by the authors) for convertability into a cellular CSC
state (Menendez et al., 2013). Apart from hypoxia, a blockade of angiogenesis (one of the hallmarks of cancer) using
MAB-based biopharmaceutical approaches (anti-VEGF
antibody) can contribute to a decrease in the survival of
CSCs and reduce drug resistance. In this regard, Bevacizumab, the only FDA-approved drug targeting VEGF, is
useful in terms of contributing towards progression-free
survival without any other beneficial changes in the overall
survival (Patel et al., 2012).
3.7. CSCs and EMT
The authors have reiterated that the acquisition of stemness
can correlated with the expression of mesenchymal
markers like vimentin, fibronectin, and N-cadherin, and
the loss of E-cadherin expression as observed in cancer
cells (Suresh and Nathawat, 2014). It has been opined that
one of the mechanisms for Her2-positive breast cancer
stem cells resistance to trastuzumab therapy involves EMT
processes in this cell type. Hence, this provides a sound,
scientific basis for developing novel HER2-based therapies
to circumvent this type of drug resistance (Bedard et al.,
2009).
4. VESLs: descendants of PGCs and precursors to stem
cells and cancer stem cells?
This paper has overlooked the existence (albeit
controversial) of VSESLs, which are less than 5 µm in size.
These cells exist in adult body organs and the expansion of
these cells may obviate the need to reprogram adult cells.
These cells do not satisfy all the criteria for stem cells. They

do not form teratomas in immunocompromised mice
and do not complement blastocysts. They are relatively
quiescent and their inability to form teratomas may be
due to their differential methylation patterns (erasure
of paternal imprinting – H19-IgF2, RasGRF1 loci, and
hypermethylation of maternally imprinted genes). These
cells were first discovered in the murine bone marrow
(CXCR4+/Oct-4+/SSEA-1+/Sca-1+/Lin−/CD45−)
by
scientists led by Dr Ratajczak’s research group from the
University of Louisville, Kentucky (USA), even though
corroborative evidence has to be obtained in suitable model
systems. Apart from the bone marrow, these cells have
also been found in several adult organs (brain, kidneys,
muscles, and the pancreas) in the same model system
(Ratajczak et al., 2008; Zuba-Surma et al., 2008). They are
thought to have originated from the migratory primordial
germ cells and were deposited in various organs during the
development of the embryo. Mobilization of these cells has
been reported in various disease conditions and could be
involved in neoplasia development. This can be inferred
from the fact that VSEL express markers are common with
primordial germ cells (PGCs) (Suresh, 2014) as well as
those cells found in the epiblast/germ line. Formation of
germinal tumors may have occurred due to an error in the
normal migratory patterns of developmentally early PGCs
(closely related to VSELs) to the genital ridges. Further,
VSELs, like cells in various tumor cell types, express cancer
testis (C/T) antigens that have a restricted germ line
expression. Hence, these cells could be the origin for the
C/T expressing tumors. Germline VSELs, like the epiblast,
the primordial stem cells, and the embryonic stem cells, also
express Oct-4, a transcription factor that is also expressed
in several tumors. Hence, it can be inferred that the VSELs
could be a source for the development of malignant
cells. The acquisition of the aforesaid critical epigenetic
changes (hypermethylation of the DMR in the Igf2-H19
locus or Rasgrf1) in VSELs may lead to the development
of certain pediatric sarcomas. This can be inferred from
the reported coincidence of such Oct4+ cells postnatally
in pediatric and young adult patients with tumors. Fairly
conclusive evidence has been obtained in patients with the
Beckwith–Wiedemann syndrome, who frequently develop
sarcomas (e.g., neuroblastoma or rhabdomyosarcoma).
Molecular analysis has shown a loss of imprinting of
the H19-Igf2 locus. An increase in pro-proliferative Igf2
levels, concomitant with a decrease in growth inhibitory
H19 protein levels, may be a contributory factor to the
initiation and development of malignancy. Further, these
patients have a cell cycle kinase inhibitor (p57KIP2) that
is downregulated. This overexpressed protein has to be
important for controlling quiescence in VSELs. It has
also been hypothesized that Oct4+ VSELs may fuse with
somatic cells (heterokaryon formation at the wrong time),
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and precede the development and selection of aneuploid,
immortal, malignant cell clones with an unstable
karyotype. These stem cells may provide early development
markers (e.g., Oct4) while their somatic partners may be
responsible for proper genomic imprinting. Last but not
least, the authors’ statement that CSCs prefer a hypoxic
environment, unlike stem cells that use glycolysis for a
lot of their energy needs, may also be reconcilable with
the existence of VSELs. It is possible the VSELs could be
recruited to the hypoxic microenvironment, wherein the

vasculature and the stroma may provide the necessary
inductive signals for their expansion. In both examples,
VSELs (normally recruited for regenerative purposes) are
erroneously mobilized to the areas of chronic inflammation
and tumor microenvironment, respectively.
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